


### REMARKS


Applicants point out that in the Restriction Requirement dated December 31, 2007, the Examiner did not appear to take into account the Preliminary Amendment dated May 25, 2006 and included in the file on PAIR. The Preliminary Amendment canceled claims 1-8, 10-12, 17-19, 30-33, and 35; amended claims 9, 15, 20, 21, 26, 34, and 36-57; and presented new claims 58-69. There was also an amendment to the specification referencing the prior-filed application. Since the Preliminary Amendment was filed within the later of 4 months from the date the National Stage commenced under 35 U.S.C. 371 or 16 months from the filing of the prior-filed application, Applicants were not required to provide a petition and surcharge to complete the priority claim.

Therefore, Applicants respectfully request the Examiner acknowledge that the Preliminary Amendment dated May 25, 2006 is formerly on the record and that the Restriction Requirement be reconsidered and recast in light thereof and of the amendments made in this Reply.


As pointed out previously, the compounds claimed in claims 58 – 69 correspond to compounds 106d, 106n, 107c, 107d, 107e, 107f, 107g, 107k, 107l, 107m, and 107n disclosed in the specification on pages 232, 236- 240, 292, and 293. Therefore, no new matter is presented. The structures of said compounds are as follows:




t-butyl-1-[9-[1-(tert-butyloxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate




Diethyl 10-oxo-2,2,18,18-tetramethyl-nonadecanedioate




11-(1-Carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid




1-[9-(1-Carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid




11-(1-Carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid




1-[9-(1-Carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid




1-[9-(1-Carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid




13-(1-Carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid



1-[11-(1-Carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropane carboxylic acid



1-[11-(1-Carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentane carboxylic acid



10-Oxo-2,2,18,18-tetramethyl-nonadecanedioic acid

In the alternative and to leave no doubt that this Reply is responsive to the pending restriction requirement, Applicants hereby elect Group L, original claims 20, 34, and 35. Group L is defined on page 6 of the Restriction Requirement as:

L. Claims 20, 34-35, drawn to none of the examples above but other compounds within the scope of the claims. The compounds must be disclosed in the specification. Structures of the compounds must be submitted and if more than one species a generic formula embracing all the species must also be submitted. This group may be subject to further restriction.

The compounds that are elected and covered by the pending claims are drawn to none of the examples above, they are specifically disclosed in the specification, and structures of the compounds are provided above. While a generic formula embracing all of the compounds has not been provided a generic claim listing all of the species has been.

The current pending claims as amended are sufficiently narrow that no restriction is deemed necessary and the method of treatment claims may be considered along with the compound and composition claims without presenting an undue burden on the Examiner.

Pending claims 34, 36, and 56-69, as amended, are patentable. Applicants respectfully request the Examiner grant early allowance of this application. The Examiner is invited to contact the undersigned attorneys for the Applicant via telephone if such communication would expedite this application.

Respectfully submitted,

Dated: June 27, 2008

/WRB/

William R. Boudreaux, Reg. No. 35,796  
Attorney for Applicants

BRINKS HOFER GILSON & LIONE  
524 SOUTH MAIN STREET  
SUITE 200  
ANN ARBOR, MICHIGAN 48104-2921  
PHONE: (734) 302-6000  
FAX: (734) 994-6331